14th Sep 2021 19:37
Renalytix PLC - Cardiff, Wales-based clinical diagnostics for kidney disease - Company and the Mount Sinai Health System announced the scaled-up implementation of the KidneyIntelX early-stage risk assessment testing and care management program.
By the end of 2021, Mount Sinai expects to provide KidneyIntelX testing and downstream care management at a rate of 300 patients per week with around 6,000 eligible patients tested by the second quarter of 2022 under the development program.
"Our KidneyIntelXTM enabled diabetic kidney disease program allows us to provide a high standard of care in early-stage kidney disease patients where we have the best chance to help patients avoid significant kidney damage. Ongoing analysis and sharing of doctor and patient user experience combined with population level data insights is helping to drive system-wide access to early-stage risk-assessment and treatment," says Robert Fields, executive vice-president at Mount Sinai Health System.
Current stock price: 778.00 pence, down 6.3%
Year-to-date change: up 60%
By Dayo Laniyan; [email protected]
Copyright 2021 Alliance News Limited. All Rights Reserved.
Related Shares:
Renalytix Plc